ArticleEvidence-based complementary and alternative medicine : eCAM2020
Ginsenoside Rg1 Induces Apoptotic Cell Death in Triple-Negative Breast Cancer Cell Lines and Prevents Carcinogen-Induced Breast Tumorigenesis in Sprague Dawley Rats.
Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Emerging and underexplored ginsenosides in cancer therapy (2020-2025): Beyond cytotoxic mechanisms.Journal of ginseng research · 2026Review
- Research Progress on Anticancer Mechanism of Ginsenoside Regulating Tumor Microenvironment.Current issues in molecular biology · 2026Review
- Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives in Complementary Medicine.Food science & nutrition · 2026Review
- Ginsenoside Rg1 inhibits angiogenesis in diabetic retinopathy through the miR-100-3p/FBXW7/c-MYC molecular axis.Journal of diabetes investigation · 2025Article
- Ginsenoside Rg1 inhibits multiple myeloma and overcomes bortezomib resistance through AMPK-mTOR pathway.Heliyon · 2024Article
- Systematic exploration of therapeutic effects and key mechanisms of Panax ginseng using network-based approaches.Journal of ginseng research · 2024Article
- MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.Aging and disease · 2024Review
- Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer.Chinese medicine · 2023Review
- Polymer-Based Wound Dressings Loaded with Ginsenoside Rg3.Molecules (Basel, Switzerland) · 2023Review
- Anticancer therapeutic effect of ginsenosides through mediating reactive oxygen species.Frontiers in pharmacology · 2023Review
- Ginsenoside Rg1 as a promising adjuvant agent for enhancing the anti-cancer functions of granulocytes inhibited by noradrenaline.Frontiers in immunology · 2023Article
- Updating the therapeutic role of ginsenosides in breast cancer: a bibliometrics study to an in-depth review.Frontiers in pharmacology · 2023Review
- Anti-cancer effect and potential microRNAs targets of ginsenosides against breast cancer.Frontiers in pharmacology · 2022Review
- Ginsenoside Rg1 Alleviates Acute Ulcerative Colitis by Modulating Gut Microbiota and Microbial Tryptophan Metabolism.Frontiers in immunology · 2022Article
- Role of Phytonutrients in Nutrigenetics and Nutrigenomics Perspective in Curing Breast Cancer.Biomolecules · 2021Review
- Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to investigate the anticancer potential of ginsenoside Rg1 using
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.